| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NTLA | Common Stock | Options Exercise | $348K | +26K | +1087.41% | $13.40 | 28.4K | Aug 4, 2021 | Direct | |
| transaction | NTLA | Common Stock | Sale | -$199K | -1.47K | -5.18% | $135.47 | 26.9K | Aug 4, 2021 | Direct | F1, F2 |
| transaction | NTLA | Common Stock | Sale | -$932K | -6.81K | -25.31% | $136.79 | 20.1K | Aug 4, 2021 | Direct | F1, F3 |
| transaction | NTLA | Common Stock | Sale | -$874K | -6.34K | -31.55% | $137.72 | 13.8K | Aug 4, 2021 | Direct | F1, F4 |
| transaction | NTLA | Common Stock | Sale | -$613K | -4.42K | -32.11% | $138.78 | 9.34K | Aug 4, 2021 | Direct | F1, F5 |
| transaction | NTLA | Common Stock | Sale | -$388K | -2.77K | -29.67% | $139.85 | 6.57K | Aug 4, 2021 | Direct | F1, F6 |
| transaction | NTLA | Common Stock | Sale | -$571K | -4.05K | -61.7% | $140.73 | 2.52K | Aug 4, 2021 | Direct | F1, F7 |
| transaction | NTLA | Common Stock | Sale | -$17.8K | -126 | -5.01% | $141.63 | 2.39K | Aug 4, 2021 | Direct | F1, F8 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NTLA | Stock Option (right to buy) | Options Exercise | $0 | -26K | -19.26% | $0.00 | 109K | Aug 4, 2021 | Common Stock | 26K | $13.40 | Direct | F9 |
| Id | Content |
|---|---|
| F1 | The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.18 to $135.885, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.25 to $137.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.255 to $138.25, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.31 to $139.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.395 to $140.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.395 to $141.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. |
| F8 | Includes shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan as follows: 760 shares on December 31, 2019; 847 shares on June 30, 2020; 561 shares on December 31, 2020 and 223 shares on June 30, 2021. |
| F9 | The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 53,437 shares as of August 4, 2021. |